5-azacytidine DPI (NHT102)
/ Nob Hill Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 09, 2026
Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer
(clinicaltrials.gov)
- P1/2 | N=100 | Not yet recruiting | Sponsor: Nob Hill Therapeutics, Inc.
New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1